Eledon Pharmaceuticals, Inc. (ELDN) AI Dilution Summary

Cash was $88,756,000 at 2026-06-30, against estimated monthly burn of $7,548,167. The company has an active at-the-market program through Guggenheim Securities, LLC, authorised to $75,000,000, with $0 sold to date. The main source of potential dilution is the S-3 shelf 333-295498, registered to $500,000,000 with $500,000,000 remaining and expiring 2029-05-11.